Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04627077 · ClinicalTrials.gov registry record
Livestrong Cancer Institutes' Patient Reported Outcomes Study
A clinical trial of Neoplasms and Drug Therapy, sponsored by University of Texas at Austin.
- Completed
- Registry status
- 121
- Enrollment target
- 1
- Study location
NCT04627077: Completed study of Neoplasms and Drug Therapy, sponsored by University of Texas at Austin.
NCT04627077 is a study of Neoplasms and Drug Therapy that has completed, run by University of Texas at Austin. The registered enrollment target is 121 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04627077, a study of Neoplasms and Drug Therapy, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- 121 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study will be to collect baseline patient reported outcome measures at the Livestrong Cancer Institutes (LCI) with the goal of improving quality care and to inform decision making by patients, providers, and researchers for future LCI initiatives.
Primary Outcome
Functional Assessment of Cancer Therapy (FACT-G)
Conditions Studied
Study Locations (1)
Texas
- Dell Seton Medical Center - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2018-01-22 |
| Est. Completion | 2019-01-25 |
What the finished NCT04627077 record still lists
NCT04627077 is an observational study that tracks outcomes without assigning an intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT04627077 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04627077 about?
NCT04627077 is a clinical study titled "Livestrong Cancer Institutes' Patient Reported Outcomes Study". The goal of this study will be to collect baseline patient reported outcome measures at the Livestrong Cancer Institutes (LCI) with the goal of improving quality care and to inform decision making by patients, providers, and researchers for future LCI initiatives.
What is the current status of trial NCT04627077?
This trial is currently completed. The enrollment target is 121 participants. The study started on 2018-01-22. Estimated completion is 2019-01-25.
What conditions does trial NCT04627077 study?
This clinical trial studies the following conditions: Neoplasms, Drug Therapy.
Who is sponsoring clinical trial NCT04627077?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04627077 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04627077's enrollment target sits among peer trials
121 64th of 158 higher than 95 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Resilience in East Asian Immigrants for Advance Care Planning Discussions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI